Advances in Clinical Care for Patients with Alcohol Dependence
neuroscienceCME TV
Premiere Date: Wednesday, February 13, 2008This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1™)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Addiction Professionals (NAADAC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, February 13, 2009
Note: Credit Is No Longer Available
 | Robert R. Conley, MD (Moderator) Distinguished Scholar, Eli Lilly and Company Adjunct Professor of Psychiatry and Pharmacy Science University of Maryland, Baltimore Baltimore, MD |
 | Michael W. Carlton, MD Chief Executive Officer, Phoenix Recovery Medical Director, Community Bridges Phoenix St. Luke's Chemical Dependence Unit Phoenix, AZ |
 | Christopher W. Shea, MA, CRAT, CAC-AD Clinical Director Father Martin’s Ashley Havre de Grace, MD |
Psychosocial interventions have been the mainstay of treatment for patients with alcohol dependence. However, there are
some patients who are not able to remain abstinent with counseling alone and medication can be an additional, effective
aid in the recovery process. The National Institute on Alcohol Abuse and Alcoholism, in its 2005 update, Helping Patients
Who Drink Too Much, states: "All approved drugs have been shown to be effective adjuncts to the treatment of alcohol
dependence. Thus, consider adding medication whenever you're treating someone with active alcohol dependence or
someone who has stopped drinking in the past few months but is experiencing problems such as craving or slips. Patients
who have previously failed to respond to psychosocial approaches alone are particularly strong candidates."(1)
Overall, psychosocial interventions target the cortex, the center for decision-making; whereas, pharmacotherapy targets
other brain areas such as the limbic region, associated with brain reward pathways.(2,3) In a study by Anton and colleagues,
patients who were given a combination of pharmacotherapy and psychosocial treatment were less likely to relapse. Those
who did relapse experienced a longer time between relapses. Thus, this study demonstrates the underlying impact that
neurobiology can have on recovery.(4)
In this evidence-based neuroscienceCME TV format, faculty will present patient cases as they explore the integration
of pharmacotherapy into current psychosocial treatment models to improve outcomes for patients with alcohol
dependence.
- NIAAA. Helping patients who drink too much: NIH Government Publications; 2005. Available at: http://www.niaaa.nih.gov/Publications/EducationTrainingMaterials/guide.htm. Accessed October 26, 2007.
- Dom G, Sabbe B, Hulstijn W, van den Brink W. Substance use disorders and the orbitofrontal cortex: systematic review of behavioural decision-making and neuroimaging studies. Br J Psychiatry 2005;187:209-220.
- Kalivas P, Volkow N. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-1413.
- Anton RF, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 2005;25:349-357.
To evaluate evidence-based psychosocial intervention and pharmacotherapy management strategies to improve outcomes for patients with alcohol dependence and to recognize the importance of neurobiology in addiction.
At the end of this CE activity, participants should be able to:
- Recognize the importance of neurobiology in addiction.
- Identify evidence-based interventions used to integrate pharmacotherapy and counseling.
- Evaluate available pharmacotherapies for patients with alcohol dependence.
- Review the clinical challenges of incorporating pharmacotherapy into treatment for patients with alcohol dependence.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, addiction counselors, and other healthcare professionals interested in alcohol dependence.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.
CME Outfitters, LLC, designates this educational activity for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians
should only claim credit commensurate with the extent of
their participation in the activity.
CNE Credit (Nurses):
CME Outfitters, LLC, is an approved
provider of continuing nursing education by the New York
State Nurses Association, an accredited approver by the
American Nurses Credentialing Center’s Commission on
Accreditation.
It has been assigned code 6WASUP-PRV-0626. 1.0 contact
hours will be awarded upon successful completion.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
CEP Credit (Psychologists):
CME Outfitters is approved
by the American Psychological Association to sponsor
continuing education for psychologists. CME Outfitters
maintains responsibility for this program and its content.
(1.0 CE credits)
NASW Credit (Social Workers):
This program was approved
by the National Association of Social Workers (provider
#886407722) for 1 continuing education contact hour.
NAADAC Credit (Addiction Professionals):
CME Outfitters, LLC, is an approved education provider by NAADAC, the Association for Addiction Professionals. Provider Number 636. This activity is designated for 1.0 contact hour.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-000-08-002-L01-P (live presentation) 376-000-08-002-H01-P (recorded programs)
Post-tests, credit request forms, and activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). Otherwise, participants should fully complete and return both the credit request form and activity evaluation located within the course guide for this activity. A certificate or statement of credit will be mailed within 4-6 weeks to all who successfully complete these requirements.
Michael W. Carlton, MD
Dr. Carlton received his Bachelor’s degree in Mechanical Engineering from The University of Arizona. After attending medical school at the University of Arizona, he completed a combined Internal Medicine and Pediatric Residency program in Phoenix, Arizona. Dr. Carlton trained in the Medical and Industrial Toxicology Fellowship program through the Samaritan Regional Poison Control Center, also in Phoenix. It was at this time that Dr. Carlton began working in the field of Addiction Medicine.
Dr. Carlton is President of Accredited Internal Medicine and of Phoenix Recovery. He is the consulting Medical Director for Gatehouse Academy, a one-year residential treatment program for young adults suffering from chemical dependency. He serves as the Medical Director for Community Bridges and Phoenix St. Luke’s Chemical Dependency Units. He has detoxed tens of thousands of people in both inpatient and out patient Addiction Medicine settings and has helped thousands more win their long-term battle against addictive disorders.
Dr. Carlton is Associate Professor for the Maricopa Psychiatric Residency Training Program, Phoenix, Arizona. He has published articles in biomedicine and toxicology.
As a speaker Dr. Carlton has spoken through the United States to thousands of people about addictive disorders and the treatment of persons suffering from them.
Christopher W. Shea, MA, CRAT, CAC-AD
Mr. Shea is currently the Clinical Director of Fr. Martin’s Ashley. In this capacity, he oversees all aspects of the treatment program for Ashley, one of the premier residential alcohol and drug rehabilitation facilities in the world. He has been a member of the counseling staff since 2001.
Mr. Shea brings 14 years of experience, working in Baltimore City and Baltimore County as a chemical dependency counselor and administrator prior to coming to Ashley. Mr. Shea received his BA in Philosophy (with a concentration in clinical psychology) from St. Hyacinth College in Massachusetts, and his master’s degree in pastoral studies from the Washington Theological Union in Washington, D.C. In addition, he is state-certified as a Chemical Dependency Counselor, board-approved as a Chemical Dependency Supervisor, and nationally certified as a Rational Addictions Therapist. He also serves as an Adjunct Professor of Chemical Dependence at Baltimore City Community College, sits on the Board of Directors for NCADD-MD, and is published in the field of chemical dependency.
Robert Conley, MD, Moderator
Dr. Conley is the Distinguished Lilly Scholar in Neuroscience. He is the former Chief of Treatment Research at the Maryland Psychiatric Research Center. After earning a degree in Natural Science from the Johns Hopkins University, Dr. Conley received his medical degree from the University of Maryland Baltimore and completed a residency at the University of Pittsburgh in psychiatry. He is the past Chairman of the Institutional Review Board for the National Institute on Drug Abuse and also the University of Maryland, Baltimore.
Dr. Conley’s work focuses on comparing the clinical effects of antipsychotics and developing new treatments for severe mental illness. Dr. Conley was the principal investigator of many studies in this area sponsored by the National institute if Mental Health, the National Institute on Drug Abuse, the Stanley Research Foundation and The National Alliance for Research in Schizophrenia and Affective Disorders.
Dr. Conley is the author of a number of publications in journals such as the Journal of Psychopharmacology, the American Journal of Psychiatry, Archives of General Psychiatry, Schizophrenia Research, and the Journal of Clinical Psychopharmacology and is a member of the American College of Neuropsychopharmacology, the Society for Neuroscience, and the Society of Biological Psychiatry. Dr. Conley is the former Editor-In-Chief of Clinical Schizophrenia & Related Psychoses.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Carlton has disclosed that he is on the speakers bureaus of Alkermes, Inc., Cephalon, Inc., Forest Pharmaceuticals, Inc., and Takeda Pharmaceuticals North America, Inc.
Mr. Shea has no financial relationships to disclose in regard to the products and/or services discussed in this activity.
Dr. Conley has disclosed that he serves as a consultant to AstraZeneca Pharmaceuticals, Eli Lilly and Company, Janssen LP, Johnson & Johnson, and Wyeth Pharmaceuticals.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, Alkermes, Inc., and Cephalon, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-053-021308-15
